Caroline Wilhelmer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Caroline Wilhelmer has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Lisa Kriegl
BioTechMed Graz , Graz
2 shared publications - Robert Krause
BioTechMed Graz , Graz
2 shared publications - Stefan Hatzl
Intensive Care Unit, Department of Internal Medicine, Medical University of Graz , Graz
2 shared publications - Alexander Christian Reisinger
Department of Internal Medicine, Intensive Care Unit, Medical University of Graz, Graz, Austria
1 shared publication - Christina Geiger
Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz , Graz
1 shared publication - Florian Krammer
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
1 shared publication
Latest Publications
- Open Access
- 17 October 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Empirical Antifungal Treatment of Critically Ill Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Bayesian Perspective
We reanalyzed 172 critically ill patients with influenza-associated ARDS in a Bayesian framework. Empirical mold-active antifungal treatment yielded a posterior median hazard ratio for influenza-associated pulmonary aspergillosis of 0.51 (95% credible interval 0.20-1.17; probability of benefit 94%), without mortality benefit. Findings remained consistent across skeptical, non-informative and externally informed priors.
- 17 October 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessEmpirical Antifungal Treatment of Critically Ill Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Bayesian Perspective
We reanalyzed 172 critically ill patients with influenza-associated ARDS in a Bayesian framework. Empirical mold-active antifungal treatment yielded a posterior median hazard ratio for influenza-associated pulmonary aspergillosis of 0.51 (95% credible interval 0.20-1.17; probability of benefit 94%), without mortality benefit. Findings remained consistent across skeptical, non-informative and externally informed priors.
- Open Access
- 15 September 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (3) , e485-e493
Empirical Antifungal Treatment of Critically Ⅲ Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study
Background: Influenza-associated pulmonary aspergillosis (IAPA) is a significant fungal complication in patients with influenza-induced acute-respiratory-distress-syndrome (ARDS). The impact of empirical antifungal treatment on IAPA incidence and outcomes remains unclear. Methods: In this observational multicenter study (9 treatment centers), we included all consecutive patients admitted to intensive care units (ICUs) with influenza-associated ARDS between 1 September 2016 and 1 March 2025. We compared patients receiving empirical antifungal treatment with those who did not, focusing on 30-day IAPA incidence (primary outcome) and survival (secondary outcome). Propensity score weighting was used to account for baseline characteristic imbalances. IAPA cases were classified based on the Fungal-Infections-in-Adult-Patients-in-ICU (FUNDICU) consensus criteria. Results: We included 172 patients, 61 (35%) of whom received empirical antifungal therapy (94% posaconazole). IAPA was diagnosed in 24 cases, with a median onset of 2 days after ICU admission. Of these, 20 occurred in the non-treatment group and 4 in the empirical treatment group. The 30-day IAPA incidence was 7.7% in the treatment group and 20.4% in the non-treatment group (P = .002). The sub-distributional hazard ratio (sHR) for IAPA incidence in the empirical treatment group compared with the non-treatment group was 0.21 (95% CI: 0.10–0.92, P = .045). However, there was no significant difference in 30-day ICU survival. Conclusions: In ICU patients with influenza ARDS, empirical antifungal treatment was associated with significantly reduced IAPA incidence, but this did not translate into improved survival. Randomized controlled trials are warranted to evaluate the efficacy and safety of patients’ specific empirical antifungal treatment with regard to IAPA incidence and outcomes.
- 15 September 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (3) , e485-e493
Open AccessEmpirical Antifungal Treatment of Critically Ⅲ Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study
Background: Influenza-associated pulmonary aspergillosis (IAPA) is a significant fungal complication in patients with influenza-induced acute-respiratory-distress-syndrome (ARDS). The impact of empirical antifungal treatment on IAPA incidence and outcomes remains unclear. Methods: In this observational multicenter study (9 treatment centers), we included all consecutive patients admitted to intensive care units (ICUs) with influenza-associated ARDS between 1 September 2016 and 1 March 2025. We compared patients receiving empirical antifungal treatment with those who did not, focusing on 30-day IAPA incidence (primary outcome) and survival (secondary outcome). Propensity score weighting was used to account for baseline characteristic imbalances. IAPA cases were classified based on the Fungal-Infections-in-Adult-Patients-in-ICU (FUNDICU) consensus criteria. Results: We included 172 patients, 61 (35%) of whom received empirical antifungal therapy (94% posaconazole). IAPA was diagnosed in 24 cases, with a median onset of 2 days after ICU admission. Of these, 20 occurred in the non-treatment group and 4 in the empirical treatment group. The 30-day IAPA incidence was 7.7% in the treatment group and 20.4% in the non-treatment group (P = .002). The sub-distributional hazard ratio (sHR) for IAPA incidence in the empirical treatment group compared with the non-treatment group was 0.21 (95% CI: 0.10–0.92, P = .045). However, there was no significant difference in 30-day ICU survival. Conclusions: In ICU patients with influenza ARDS, empirical antifungal treatment was associated with significantly reduced IAPA incidence, but this did not translate into improved survival. Randomized controlled trials are warranted to evaluate the efficacy and safety of patients’ specific empirical antifungal treatment with regard to IAPA incidence and outcomes.